These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
177 related items for PubMed ID: 3297068
1. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Siddik ZH, Newell DR, Boxall FE, Harrap KR. Biochem Pharmacol; 1987 Jun 15; 36(12):1925-32. PubMed ID: 3297068 [Abstract] [Full Text] [Related]
2. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Cancer Res; 1984 Apr 15; 44(4):1693-7. PubMed ID: 6367971 [Abstract] [Full Text] [Related]
3. Comparative distribution and excretion of carboplatin and cisplatin in mice. Siddik ZH, Jones M, Boxall FE, Harrap KR. Cancer Chemother Pharmacol; 1988 Apr 15; 21(1):19-24. PubMed ID: 3277732 [Abstract] [Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR. Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598 [Abstract] [Full Text] [Related]
5. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats. Láznícková A, Láznícek M, Kvĕtina J, Drobník J. Cancer Chemother Pharmacol; 1986 Nov 15; 17(2):133-6. PubMed ID: 3521926 [Abstract] [Full Text] [Related]
6. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Cancer Res; 1986 Apr 15; 46(4 Pt 2):1972-9. PubMed ID: 3512077 [Abstract] [Full Text] [Related]
7. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats. Ueda T, Yasumasu T, Uozumi J. J Toxicol Sci; 1991 Aug 15; 16(3):101-9. PubMed ID: 1942134 [Abstract] [Full Text] [Related]
8. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. Sharma H, Thatcher N, Baer J, Zaki A, Smith A, McAucliffe CA, Crowther D, Owens S, Fox BW. Cancer Chemother Pharmacol; 1983 Aug 15; 11(1):5-7. PubMed ID: 6349844 [Abstract] [Full Text] [Related]
10. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro). Perera A, Jackson H, Sharma HL, McAuliffe CA, Fox BW. Chem Biol Interact; 1992 Dec 15; 85(2-3):199-213. PubMed ID: 1493609 [Abstract] [Full Text] [Related]
11. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. Daley-Yates PT, McBrien DC. Biochem Pharmacol; 1985 May 01; 34(9):1423-8. PubMed ID: 4039567 [Abstract] [Full Text] [Related]
12. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S. Cancer Chemother Pharmacol; 1989 May 01; 23(4):243-6. PubMed ID: 2647312 [Abstract] [Full Text] [Related]
13. Atypical pharmacokinetics and excretion of new platinum analogues in rodents. Webster LK, Ellis AG, Apicella C, Deacon GB. Cancer Chemother Pharmacol; 2002 Jan 01; 49(1):87-92. PubMed ID: 11855757 [Abstract] [Full Text] [Related]
14. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Boughattas NA, Hecquet B, Fournier C, Bruguerolle B, Trabelsi H, Bouzouita K, Omrane B, Lévi F. Biopharm Drug Dispos; 1994 Dec 01; 15(9):761-73. PubMed ID: 7888604 [Abstract] [Full Text] [Related]
15. Pharmacokinetics of carboplatin after i.v. administration. Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, Pinedo HM. Cancer Treat Rep; 1987 Dec 01; 71(12):1231-7. PubMed ID: 3319135 [Abstract] [Full Text] [Related]
16. Effect of oxoplatinum and CBDCA on renal functions in rats. Láznícková A, Semecký V, Láznícek M, Zubr V, Koksál J, Kvĕtina J. Neoplasma; 1989 Dec 01; 36(2):161-9. PubMed ID: 2654665 [Abstract] [Full Text] [Related]
17. [Pharmacokinetic properties of platinium derivatives]. Boisdron-Celle M, Lebouil A, Allain P, Gamelin E. Bull Cancer; 2001 Aug 01; 88 Spec No():S14-9. PubMed ID: 11567909 [Abstract] [Full Text] [Related]
18. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. Rahman A, Roh JK, Wolpert-DeFilippes MK, Goldin A, Venditti JM, Woolley PV. Cancer Res; 1988 Apr 01; 48(7):1745-52. PubMed ID: 3162402 [Abstract] [Full Text] [Related]
19. Biliary excretion of platinum in rats after administration of cisplatin and aqua(1,1-bis(aminomethyl)-cyclohexane)sulfatoplatinum(II) (spiroplatin, TNO-6). Van der Vijgh WJ, Verbeek PC, Klein I, Pinedo HM. Cancer Lett; 1985 Aug 01; 28(1):103-9. PubMed ID: 4040805 [Abstract] [Full Text] [Related]
20. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J. Cancer Res; 1984 Nov 01; 44(11):5432-8. PubMed ID: 6386150 [Abstract] [Full Text] [Related] Page: [Next] [New Search]